# Psyence Biomedical LTD.: Form 20-F for the period ended Mar 31, 2025

- Company: [Psyence Biomedical LTD.](/companies/pbm.md) (CIK 1985062)
- Form: 20-F
- Filed: 2025-06-25
- Accepted by EDGAR: Jun 25, 2025, 21:16 ET
- Period: 2025-03-31
- Accession: 0001213900-25-057893
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea0246623-20f_psyence.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Net income | 12 months, 2024-04-01 to 2025-03-31 | $1.0m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2024-04-01 to 2025-03-31 | $5.24 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2024-04-01 to 2025-03-31 | $5.24 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2024-04-01 to 2025-03-31 | −$3.7m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-04-01 to 2025-03-31 | $9.9k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2025-03-31 | $6.1m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2025-03-31 | $6.6m | ifrs-full:CurrentAssets |
| Total assets | at 2025-03-31 | $7.3m | ifrs-full:Assets |
| Total liabilities | at 2025-03-31 | $594.4k | ifrs-full:Liabilities |
| Shareholders' equity | at 2025-03-31 | $6.7m | ifrs-full:Equity |
| Shares outstanding | at 2025-03-31 | 568,021 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea0246623-20f_psyence.htm

Filed Jun 25, 2025.
Source: SEC EDGAR, the filing index for accession 0001213900-25-057893. Last ingested by Listed: Oct 24, 2026, 15:16 ET. No prices; not investment advice.